TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02500550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATIR101
Description: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation (HSCT)
Description: CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TBI regime
Description: * Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-TBI regime
Description: * Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.
Study: NCT03371719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT02333708

Intervention type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Intervention: Blood sample
Study: NCT01047410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention and dietary advice
Description: The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
Study: NCT04038333

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any interventions.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any interventions.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any interventions.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any interventions.
Study: NCT02605577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new systemic nutrition management protocol
Description: a new established systemic nutrition management protocol
Study: NCT02721862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
Study: NCT00834249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting
Study: NCT03853005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVHDF
Description: Patients will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: controlled
Description: Patients will receive the usual care
Study: NCT00041392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 100 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Placebo
Study: NCT02069080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64-Cu-plerixafor
Description: Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion.
Study: NCT02005497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthLinks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HealthLinks
Study: NCT01250080

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition with Glutamine
Description: daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Total Parenteral Nutrition without glutamine
Description: The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
Study: NCT03848507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin 20%
Description: Intravenous administration of 20% albumin during cystectomy
Study: NCT01543360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary strategy
Description: The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subclavian strategy
Description: The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
Study: NCT02622386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule taken daily for 12 weeks.
Study: NCT02721862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Gallbladder Ultrasound
Description: Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallbladder Ultrasound
Description: Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
Study: NCT01645163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling using mobile phones
Description: Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
Study: NCT05076968

Intervention type: PROCEDURE
Intervention: Complete denture fabrication
Description: Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery

Intervention type: PROCEDURE
Intervention: Complete denture fabrication
Description: Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
Study: NCT02354950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30mg
Description: GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30mg
Description: GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30mg
Description: GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30mg
Description: GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
Study: NCT04518410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SNG001
Description: Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Camostat
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Study: NCT03376828

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Endotracheal intubation time using the Macintosh laryngoscope
Study: NCT04518410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAB-185 (low dose)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986414 + BMS-986413
Description: Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AZD7442 (IV)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AZD7442 (IM)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study: NCT02890992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT03491072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive IV fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients will receive IV fentanyl
Study: NCT01183910

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrus Bioflavanoid Blend
Description: Pill Taken Twice a Day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Oral Tablet Taken Twice a Day
Study: NCT04518410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAB-185 (high dose)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study: NCT02889380

Intervention type: DRUG
Intervention: No Intervention
Description: This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
Study: NCT04518410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bamlanivimab 700mg
Description: Administered by single IV infusion. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bamlanivimab 700mg
Description: Administered by single IV infusion. Participants are no longer being randomized to this intervention.
Study: NCT01117545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: Six sessions of EFT
Study: NCT04549428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
Study: NCT03376828

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Endotracheal intubation time using the Macintosh laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac Videolaryngoscope
Description: Endotracheal intubation time using the C-Mac Videolaryngoscope

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: C-Mac Videolaryngoscope
Description: Endotracheal intubation time using the C-Mac Videolaryngoscope
Study: NCT03007277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANJO
Description: PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
Study: NCT00153530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: whole-brain irradiation
Study: NCT00852020

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutrition supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral nutrition supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks
Study: NCT00609674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Description: Fluticasone furoate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02687126

Intervention type: DEVICE
Group type: OTHER
Intervention: Central Venous Catheterization
Description: Ultrasound guided internal jugular venous catheterization
Study: NCT04134091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1144 Formulation A
Description: Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as 225 mg testosterone undecanoate twice daily (BID).
Study: NCT03007277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PANJO
Description: PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
Study: NCT02331264

Intervention type: OTHER
Intervention: Exposure to metal debris
Description: The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
Study: NCT02112110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-BMS-791325
Study: NCT04107220

Intervention type: DRUG
Group type: OTHER
Intervention: Sacubitril/Valsartan
Description: Effect of Sacubitril/Valsartan on BNP and NT-proBNP
Study: NCT02028949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavedos®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Study: NCT00594399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling
Description: Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
Study: NCT01440101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab (BG00002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab (BG00002)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04706572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation with external auditory bio-feedback
Description: Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stimulation with external auditory bio-feedback
Description: Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
Study: NCT04134091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1144 Formulation B
Description: Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo capsule administered as BID
Study: NCT00505622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel